synthesi
sever
combin
ritter
reaction
rearrang
noradamantan
alcohol
report
sever
novel
amin
display
low
micromolar
activ
sever
influenza
viru
strain
includ
amantadineresist
strain
compound
show
cytotox
mdck
cell
nfluenza
viru
global
caus
signific
morbid
mortal
relat
easi
transmiss
abil
escap
exist
immun
possibl
introduct
human
popul
emerg
swine
highli
pathogen
avian
influenza
virus
consid
global
health
threat
current
avail
drug
treatment
influenza
viru
infect
compris
ion
channel
blocker
amantadin
rimantadin
chart
neuraminidas
inhibitor
oseltamivir
zanamivir
howev
current
circul
influenza
strain
resist
ion
channel
blocker
resist
neuraminidas
inhibitor
particular
oseltamivir
also
rise
accordingli
novel
antiinfluenza
viru
drug
urgent
need
take
account
amantadin
initi
licens
unit
state
surpris
mani
hundr
deriv
synthes
test
includ
adamantan
adamantan
azaspiroadamantan
aminospiroadamantan
adamantan
deriv
interestingli
sever
prove
activ
amantadinesensit
strain
contain
wildtyp
wt
protein
activ
amantadineresist
strain
best
knowledg
synthes
far
explor
whether
addit
two
alkyl
group
benefici
antivir
activ
amantadin
decid
synthes
evalu
antivir
activ
seri
start
known
acid
take
advantag
uniqu
combin
ritter
reaction
meerwein
rearrang
studi
report
found
sever
display
low
micromolar
activ
sever
influenza
viru
strain
interestingli
activ
markedli
subtypedepend
compound
activ
strain
whether
carri
amantadinesensit
channel
mutat
amantadineresist
channel
neither
compound
activ
influenza
strain
stoelt
shiner
report
solvolysi
sever
ethyl
sulfon
led
excel
yield
similar
way
led
high
yield
scheme
presum
larg
releas
strain
promot
observ
rearrang
familiar
form
ritter
reaction
alcohol
treat
strong
acid
gener
carbenium
ion
nitril
react
produc
nitrilium
ion
whose
hydrolysi
afford
amid
product
thu
envisag
submit
ritter
reaction
may
led
n
amid
rearrang
initi
gener
carbenium
ion
hydrolysi
amid
lead
expect
deriv
scheme
interestingli
although
combin
ritter
reaction
meerwein
rearrang
use
mechanist
studi
combin
synthet
purpos
limit
first
studi
suitabl
approach
use
alcohol
obtain
yield
known
ester
jirgenson
et
al
describ
acetamid
result
ritter
reaction
tertiari
alcohol
difficult
hydrolyz
correspond
chloroacetamid
underw
easi
cleavag
correspond
tertalkylamin
use
thiourea
thu
reaction
tertiari
alcohol
chloroacetonitril
use
standard
condit
develop
jirgenson
et
al
led
expect
rearrang
chloroacetamid
yield
cleavag
chloroacetyl
group
thiourea
furnish
yield
scheme
success
prove
viabil
approach
synthes
seri
tertiari
alcohol
ester
alcohol
subsequ
transform
correspond
deriv
high
yield
scheme
remark
reaction
ester
methyllithium
ethyllithium
propylmagnesium
chlorid
led
expect
tertiari
noradamantyl
alcohol
good
yield
addit
excess
isopropylmagnesium
bromid
led
secondari
alcohol
similarli
reaction
pentamethylenebi
magnesium
bromid
furnish
yield
reduct
behavior
organometal
reagent
steric
encumb
keton
well
document
alcohol
may
aris
reduct
magnesium
speci
initi
obtain
alkyl
noradamantyl
keton
final
succeed
synthesi
cyclohexanol
use
known
iodid
start
materi
reaction
tbutyllithium
follow
addit
cyclohexanon
led
expect
alcohol
yield
alcohol
smoothli
underw
ritter
reaction
chloroacetamid
cleav
thiourea
amin
scheme
note
directli
obtain
rearrang
amin
use
excess
urea
trifluoroacet
acid
yield
onestep
procedur
synthesi
amin
alcohol
seem
gener
applic
procedur
alcohol
led
correspond
amin
yield
howev
yield
onestep
procedur
much
lower
overal
yield
obtain
use
cloroacetonitril
method
interestingli
approach
also
success
implement
ring
expans
bisnoradamantan
deriv
correspond
noradamantan
amin
thu
reaction
known
ester
excess
methyllithium
follow
applic
jirgenson
condit
alcohol
led
noradamantan
deriv
good
yield
scheme
gain
insight
relationship
sar
small
seri
nalkyl
n
ndialkyl
deriv
synthes
adamantylamin
use
standard
amin
chemistri
scheme
thu
reduct
alkyl
formaldehyd
acetaldehyd
benzaldehyd
nacnbh
led
amin
respect
high
yield
sever
attempt
synthes
n
ndiethylderiv
either
met
failur
probabl
consequ
steric
hindranc
alkyl
led
piperidin
deriv
low
yield
reduct
methyl
secondari
amin
formaldehyd
nacnbh
led
yield
tertiari
amin
catalyt
hydrogen
quantit
furnish
secondari
amin
similarli
n
ndimethylderiv
amin
also
synthes
high
yield
reduct
alkyl
formaldehyd
nacnbh
final
secondari
amin
synthes
treatment
methyl
chloroformi
follow
reduct
lialh
overal
yield
scheme
structur
new
compound
confirm
element
analysi
andor
accur
mass
measur
ir
h
nmr
c
nmr
mass
spectral
data
amin
fulli
character
correspond
hydrochlorid
tartrat
salt
moreov
structur
chloroacetamid
establish
xray
crystallographi
antivir
cell
cultur
assay
perform
determin
antivir
activ
synthes
compound
broad
panel
dna
rna
virus
none
compound
display
activ
envelop
dna
virus
herp
simplex
viru
vaccinia
viru
envelop
rna
virus
felin
coronaviru
viru
respiratori
syncyti
viru
vesicular
stomat
viru
sindbi
viru
punta
toro
viru
nonenvelop
rna
virus
coxsackieviru
influenza
virusinfect
canin
kidney
mdck
cell
sever
compound
display
low
micromolar
activ
influenza
subtyp
compound
activ
influenza
subtyp
tabl
antivir
data
obtain
microscop
inspect
viral
cytopath
effect
cpe
day
postinfect
confirm
colorimetr
cell
viabil
assay
anticip
compound
prove
inact
influenza
b
viru
known
insensit
amantadin
rimantadin
analysi
data
tabl
reveal
follow
trend
first
singl
except
dipropyl
deriv
primari
amin
potent
amantadin
rimantadin
strain
influenza
although
potent
compound
spiroderiv
ec
highest
select
ie
ratio
cytotox
antivir
concentr
note
compound
ec
ratio
cc
ec
second
introduct
one
two
methyl
group
primari
amin
benefici
ie
vs
practic
neutral
regard
antivir
activ
ie
vs
vs
vs
introduct
larger
group
clearli
deleteri
activ
lead
larg
inact
cytotox
compound
antivir
effect
three
compound
display
good
select
primari
amin
tertiari
amin
secondari
amin
evalu
broader
panel
influenza
virus
includ
two
amantadin
sensit
strain
chimer
strain
contain
protein
protein
includ
amantadineresist
strain
shown
tabl
three
compound
behav
similarli
show
activ
three
strain
inact
three
strain
wellknown
target
amantadin
rimantadin
influenza
viru
channel
protein
singl
mutat
suffici
render
viru
resist
drug
current
circul
strain
influenza
viru
subtyp
carri
mutat
urgent
need
develop
novel
antiinfluenza
drug
effect
common
amantadineresist
mutant
influenza
strain
use
protein
carri
two
substitut
associ
amantadin
resist
ie
strain
particularli
sensit
new
amin
result
tabl
appear
target
new
amantadin
analogu
protein
compound
display
antivir
activ
studi
strain
regardless
whether
carri
wt
amantadinesensit
mutat
amantadineresist
protein
moreov
new
deriv
inact
strain
studi
also
regardless
carri
wt
mutat
protein
sum
synthes
fulli
character
evalu
seri
novel
amantadin
analogu
six
compound
endow
ec
valu
order
magnitud
lower
amantadin
cytotox
three
new
amin
display
low
micromolar
activ
sever
strain
includ
amantadineresist
strain
inact
strain
mechan
action
compound
current
studi
manuscript
written
contribut
author
